Barr PM, et al. - This trial was formulated in order to gauge the efficacy and safety of consolidative radioimmunotherapy and sequential maintenance rituximab following chemoimmunotherapy in advanced-stage follicular lymphoma. Data disclosed near universal responses following chemoimmunotherapy and radioimmunotherapy. The occurrence of maximum discontinuations during maintenance therapy indicated that rituximab over a 4-year span was not feasible for several patients. Nevertheless, this sequential therapeutic strategy led to good overall outcomes for patients, with the inclusion of a low incidence of early disease progression.